Healthcare may not lead the next market rally, but current levels offer compelling risk/reward for contrarian investors ...

Discover how DAOs revolutionize drug discovery through decentralized funding, transparency, and community governance.

Discover Sangamo Therapeutics’ Q3 2025 highlights: clinical progress in Fabry disease, FDA support for ST-920, extended cash runway, and partnership updates.

Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $703 million Raised ...

In the run-up to the 2020 election, all 20 Democratic presidential candidates promised voters they’d pursue bold changes to ...

Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated ...

Royalty Pharma Plc (NASDAQ: RPRX) is one of the most profitable biotech stocks to buy. On October 10, Morgan Stanley analyst ...

Q3 2025 Earnings Call Transcript October 29, 2025 OPKO Health, Inc. beats earnings expectations. Reported EPS is $0.03, ...

Retired FedEx pilot Gary Dyson, an Air Force veteran, is the captain and chief pilot of the Orbis Flying Eye Hospital.

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) on October 21 with a $40 price ...

ST-920 Clinical Data -- Positive mean annualized eGFR slope of nearly 2.0 observed at 52 weeks in all 32 patients; A mean annualized eGFR slope of 1.7 was observed in 19 patients with two years of ...

Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.